SeaSpine to Host Virtual Analyst and Investor Day on March 11, 2022
SeaSpine Holdings Corporation (NASDAQ: SPNE) has announced the release date for its fourth quarter and full year 2021 financial results, set for Friday, March 11, 2022. A conference call and webcast will be held at 9:00 am PT / 12:00 pm ET. During the event, the management team will discuss the completion of the 7D Surgical integration and reveal the company's long-term strategy and capital allocation plans. Additionally, a Virtual Analyst and Investor Day will offer insights, followed by a live Q&A session. For further details, visit www.seaspine.com.
- None.
- None.
Announces Date of Fourth Quarter and Full Year 2021 Financial Results Conference Call
CARLSBAD, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release fourth quarter and full year 2021 financial results on Friday, March 11, 2022. Members of the Company’s management team will host a corresponding conference call and webcast beginning at 9:00 am PT / 12:00 pm ET and ending at 10:30 am PT / 1:30 pm ET.
Concurrently, the Company will host a Virtual Analyst and Investor Day with financial analysts and institutional investors. With the completion of the 7D Surgical integration, the Company’s management team will present the long-term strategy and capital allocation plans, followed by a live Q&A session.
To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com
FAQ
When will SeaSpine announce its fourth quarter and full year 2021 financial results?
What time is the SeaSpine financial results conference call scheduled?
How can I access the SeaSpine financial results conference call?
What will be discussed during the SeaSpine Investor Day?
Will there be a Q&A session during the SeaSpine conference call?
